Medisca and dsm–firmenich Partner to Expand Access to Pharmaceutical-Grade Vitamin APIs for U.S. Compounding Market
12.5.2026 15:00:00 CEST | Business Wire | Press Release
Medisca, a global leader in personalized pharmaceutical medicine, has entered into a strategic partnership with dsm–firmenich, a leading ingredient manufacturer serving regulated pharmaceutical markets worldwide.
Through this partnership, Medisca will make a portfolio of pharmaceutical-grade vitamin active pharmaceutical ingredients (APIs) available to U.S. compounding professionals, expanding access to ingredients manufactured within European cGMP environments and supported by established quality systems and documentation standards.
Strengthening the foundation of compounding
As compounding continues to support increasingly complex and regulated care settings, expectations around ingredient sourcing, consistency, and documentation continue to rise. Pharmacies and 503B outsourcing facilities are seeking partners that enable them to operate with confidence at scale.
This partnership reflects a long-term commitment to expanding access to high-quality ingredient solutions while preserving the workflows, relationships, and operational models customers rely on today.
“We are grateful to partner with dsm–firmenich, a global organization recognized for its manufacturing standards and commitment to quality,” said Peng Li, Vice President, Strategic Partnerships at Medisca. “Ingredient sourcing is foundational to trust and long-term success in compounding. By bringing dsm–firmenich pharmaceutical-grade API portfolio into the Medisca ecosystem, we are expanding what our customers can rely on today and supporting how the industry continues to evolve.”
The partnership introduces pharmaceutical-grade vitamin APIs through an established commercial and technical model designed to support regulated use and long-term continuity across compounding practice.
“Partnering with Medisca is a meaningful step in expanding access to high-quality, pharmaceutical-grade vitamin APIs for the U.S. compounding market. By combining our global manufacturing expertise and commitment to cGMP standards with Medisca’s deep understanding of compounding professionals, we are strengthening supply reliability and enabling pharmacies and 503B outsourcing facilities to operate with greater confidence, consistency, and quality in patient care.” ~Jennifer McManus, Senior Sales Director, dsm-firmenich
The dsm–firmenich vitamin API portfolio is available through Medisca in the United States, with additional products expected to be introduced over time. Customers can contact their Medisca sales representative for ordering information, pricing, and lead times.
About dsm–firmenich
As innovators in nutrition, health, and beauty, dsm–firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With its comprehensive range of solutions, natural and renewable ingredients, and renowned science and technology capabilities, the company creates what is essential for life, desirable for consumers, and more sustainable for people and the planet. dsm–firmenich is a Swiss company with dual headquarters in Kaiseraugst, Switzerland and Maastricht, Netherlands, listed on Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, dsm–firmenich brings progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com
About Medisca
Founded in 1989, Medisca is a leader in personalized medicine and pharmaceutical supply chain solutions, with a vast portfolio of over 2,000 products complemented by a library of 10,000+ proprietary and customized medication formulas, expertise and services in pharmaceutical compounding, continuing healthcare education, and analytical testing. Providing finely-tuned solutions to diverse wellness sectors in numerous markets globally, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all. For more information, visit www.medisca.com and follow us on LinkedIn, Facebook, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260512963697/en/
Contacts
Medisca Communications
communications@medisca.com
1-800-665-6334
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press Release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press Release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press Release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom